
GenesWell BCT Reclassifies Subset of Oncotype DX Low-Risk Patients
SEOUL, SOUTH KOREA, April 28, 2025 /EINPresswire.com/ -- Gencurix announced results from a multicenter study evaluating the prognostic stratification performance of its breast cancer assay, GenesWell BCT, compared to Oncotype DX, a widely used 21 …